OsteoporosisROSSNCT07030205
Resting-state Imaging and OSteoporosiS
A study testing Blood sample, Bone density exam and Tests and questionnaires of study in people with Osteoporosis, run by University Hospital, Clermont-Ferrand at 1 site in France.
Trial summary
This study will be conducted in 20 postmenopausal healthy volunteers, 20 postmenopausal osteoporotic patients with fracture and 20 postmenopausal osteoporotic women without fracture, in order to compare functional connectivity between brain areas. Read more about this study
- Who is it for?
- Ages 50 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Osteoporosis
- What is being tested?
- Blood sample, Bone density exam and Tests and questionnaires of study
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 66 participants
- Where
- 1 siteFrance
- Study dates
- 3 Sep 2025to 1 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Women aged 50 or over, with postmenopausal osteoporosis, fractured or not, diagnosed by their rheumatologist,
- Able to give informed consent to participate in the research,
- Affiliation with the French Social Security.
- Women aged 50 or over,
- Bone densitometry performed as part of the protocol, not suggestive of osteoporosis and validated by investigators,
- Matched to patients by age, menopausal status, socio-educational level and manual laterality,
Show all 9Show fewer
- Able to give informed consent to participate in the research,
- Affiliation with the French Social Security.
- Registration or acceptance of registration in the national register of volunteers participating in Research.
Who cannot join
- Presence of pacemaker,
- Presence of medical devices (implants or prostheses),
- Incompatibility of the patient with the safety criteria of the medical imaging center for carrying out magnetic resonance experiments at 3 Tesla,
- Contraindications to the realization of MRI without injection such as claustrophobia proven, hearing aid, pacemaker wearers, wearing a brain clip,
- Refusal to be informed in the event of the accidental discovery of an anomaly during the resting state functional magnetic resonance imaging,
- Woman under legal protection or deprived of liberty,
- Refusal to participation
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU de Clermont-Ferrand
Clermont-Ferrand
Lise Laclautre
Marie-Eva Pickering
About this study
This study will be conducted in 20 postmenopausal healthy volunteers, 20 postmenopausal osteoporotic patients with fracture and 20 postmenopausal osteoporotic women without fracture, in order to compare functional connectivity between brain areas. Participants will complete different questionnaires and tests assessing cognition, quality of life, sleep, physical activity, pain, anxiety and depression. A biological sample will be performed in order to evaluate different markers of bone remodeling. A Resting-state functional magnetic resonance imaging (rs-fMRI) will be realized in order to establish functional connectivity between brain regions.
- Conditions
- Osteoporosis
- Being tested
- Blood sample, Bone density exam, Tests and questionnaires of study, Functional connectivity value of brain networks at rest
- Keywords
- Osteoporosis, Resting state fMRI (rs-fMRI), Cognition
- Medical subject headings
- Osteoporosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blood sampleOther
A blood sample (fasting), for biobanking purposes to measure certain bone biological markers known to be indicators of bone remodeling (osteocalcin, sclerostin, periostin, irisin, procollagen type 1 N-terminal propeptide (P1NP), Dickkopf-related protein 1 (DKK1), and collagen type 1 C-terminal telopeptides (CTX)).
Bone density examOther
A bone density exam will be performed in order to verify the non-osteoporotic status of the healthy volunteers group.
Tests and questionnaires of studyOther
An assessment of cognitive functions will be realized using Montreal Cognitive Assessment (MoCA), Cantab® tests (MOT, MTS, RTI, DGS), the Trail Making Test (TMT), verbal fluency, the Stroop test, the Dubois 5-word test, and the oral picture naming test. Other questionnaires will be used, assessing: sleep quality (Pittsburgh Physical Activity Questionnaire (PSQI)), anxiety and depression (the anxiety/depression scale (HAD)), quality of life (Short Form-36 quality of life questionnaire (SF-36)), physical activity (International Physical Activity Questionnaire (IPAQ)), and pain with the Brief Pain Inventory questionnaire (BPI) and the numerical scale (EN).
Functional connectivity value of brain networks at restOther
A Resting-State Functional Magnetic Resonance Imaging will be conducted in order to evaluate and compared functional connectivity value of brain networks at rest between three groups.
| Study group | Role | What they receive |
|---|---|---|
| Postmenopausal Healthy volunteers | Experimental | 22 postmenopausal healthy women, matched by age, menopausal status, socio-educational level and manual laterality, will be included in this study Receives: Other: Blood sample; Other: Bone density exam; Other: Tests and questionnaires of study; Other: Functional connectivity value of brain networks at rest |
| Postmenopausal osteoporotic patients with fracture | Experimental | 22 Postmenopausal osteoporosis patients with fractures will be included in this study Receives: Other: Blood sample; Other: Tests and questionnaires of study; Other: Functional connectivity value of brain networks at rest |
| Postmenopausal osteoporotic patient without fracture | Experimental | 22 Postmenopausal osteoporosis patients without fractures will be included in this study. Receives: Other: Blood sample; Other: Tests and questionnaires of study; Other: Functional connectivity value of brain networks at rest |
What is being measured
The primary outcome is the main question the study is designed to answer.
Functional connectivity value of brain networks at rest
The primary outcome is the functional connectivity value of brain networks at rest, calculated from resting-state fMRI data.
Measured: At visit 2 (end of study visit, up to fifteen days after inclusion) for osteoporotic patient group and at visit 3 (end of study visit, up to one month after inclusion) for healthy volunteers group.
Secondary outcomes (23)
Evaluation of cognitive function (MoCA test)
The Montreal Cognitive Assessment (MoCA) is the most sensitive rapid assessment test, with the broadest range of cognitive functions (attention, concentration, executive functions, memory, language, visuo-constructive abilities, abstraction, calculation, orientation). Time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points; a score of 26 or above is considered normal.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Cantab test: MOT)
The Motor Screening Task provides a general assessment of whether sensorimotor deficits or lack of comprehension, will limit the collection of valid data from the participant. Coloured crosses are presented in different locations on the screen, one at a time. The participant must select the cross on the screen as quickly and accurately as possible. Outcome measures cover accuracy (Euclidean distance between finger and target) and difficulty speed adjustment.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (CANTAB test: Reaction Time (RTI)
Reaction Time provides assessments of motor and mental response speeds, as well as measures of movement time, reaction time, response accuracy and impulsivity. The participant must select and hold a button at the bottom of the screen. Circles are presented above (one for the simple mode, and five for the five-choice mode). In each case, a yellow dot will appear in one of the circles, and the participant must react as soon as possible, releasing the button at the bottom of the screen, and selecting the circle in which the dot appeared. Outcome measures are divided into reaction time and movement time for both the simple and five-choice variants.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (CANTAB test: Digit Span)
Digit Span (DGS) is a measure of verbal short term and working memory. The participant will hear a sequence of digits and then immediately be prompted to verbally repeat the sequence, either as it was heard (forwards), or in reverse order (backwards). If the participant responds correctly, the next trial presents a longer sequence. The task terminates when participants responded incorrectly on three occasions at a span length. The participant's span is the longest number of sequential digits that can accurately be remembered. Outcome measures include the direction of the task (forwards or backwards), the longest sequence successfully reached and passed, and the total number of attempts.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (CANTAB test: Match to Sample Visual Search)
Match to Sample Visual Search assesses attention and visual searching, with a speed accuracy trade-off. The participant is shown a complex visual pattern in the middle of the screen. After a brief delay, a varying number of similar patterns are shown in a circle of boxes around the edge of the screen. Only one of these patterns matches the pattern in the centre of the screen, and the participant must indicate which it is by selecting it. The outcome measures for this task cover accuracy and reaction time.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Trail Making Test)
The Trail Making Test is a neuropsychological test of visual attention and task switching. It can provide information about visual search speed, scanning, speed of processing, mental flexibility, as well as executive functioning. There are 2 parts to the TMT. Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order. In Part B, the circles include both numbers (1-13) and letters (A-L); The subject must correctly connect the circles as quickly as possible, within a limit of 100 seconds for part A and 300 seconds for part B. For each part, the completion time and the number of errors are collected.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Stroop test)
The Stroop Color Test assesses selective attention and the ability to inhibit cognitive interference, which occurs when the processing of one feature of a stimulus affects the simultaneous processing of another feature of the same stimulus. This test consists of three conditions:
- Color Naming (the instruction is to name the color of green, red, and blue squares),
- Reading "color name" words (the words "red," "blue," and "green" are printed in black),
- Interference (the instruction is to name the ink color of the "color name" words, printed in a different ink color-for example, the word "blue" is printed in red).
For each condition, a sheet of 50 items is presented to the participant, and the total time is recorded (within a limit of 90 seconds for Conditions 1 and 2, and 180 seconds for Condition 3), as well as the number of corrected and uncorrected errors.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Verbal fluency test)
Verbal fluency is used to assess executive functions. This test is a simple language production test. This test assesses semantic fluency or categorical fluency. This is done by asking the participant to name as many nouns as possible in a given category in two minutes. Words from the same family and proper nouns should not be mentioned, and the participant should not repeat themselves. A score will be calculated based on the number of words given and the number of errors made.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (5 words test)
The 5-word test is divided into two different stages. The first allows us to check the encoding of the information to be remembered. To do this, the subject will be shown a list of 5 words that they will have to read aloud and remember. To ensure memorization, the subject will be immediately questioned about the words they have just remembered. If necessary, clues may be provided. Once this first stage is completed, an intercurrent attentional test will be carried out. Its purpose is to divert the subject's attention for a sufficient time (between 3 and 5 minutes). At the end of the intercurrent test, the participant is again asked for the 5 words they previously remembered. Once again, clues may be provided if necessary. The data collected are the scores for immediate recall and delayed recall, with and without cueing.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Oral Picture Naming Test)
The oral picture naming test highlights the extent of the patient's potential word deficit and provides valuable insights into the process of impaired speech when analyzing the nature of the errors. During this test, the subject will be presented with cards representing objects. The subject must name the object presented. In this study, 20 cards will be presented to the participants. The data collected include the number of correctly named images and the type of errors.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
The Pittsburgh Sleep Quality Index (PSQI)
The PSQI is a self-administered questionnaire with 19 items. It was developed to measure sleep quality in the month prior to the patient interview. This questionnaire includes 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbance, hypnotic medication use and daytime dysfunction.
The global score (0 to 21) is obtained by adding the sub-scores of the 7 components, each ranging from 0 to 3 points. In the absence of an answer to one or more questions, the subtotal using this question cannot be calculated and will affect the overall score.
The higher the overall score, the greater the impairment in sleep quality. An overall score >5 is an indicator of sleep disturbance.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of pain: The Brief Pain Inventory Questionnaire (BPI)
This self-assessment scale allows the patient to characterize the pain in terms of its intensity and its psychosocial repercussions by means of 11 scales rated from 0 (no pain or does not bother) to 10 (the most horrible pain you can imagine or completely bothers you).
The BPI also asks the patient to black out the painful areas on a diagram (front and back) and to put an "S" if the pain is on the surface or a "P" if it is deep. The questionnaire also asks the patient to indicate what treatment or medication he or she is taking for the pain and what percentage improvement has been obtained.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of pain: Numerical pain scale
This scale allows the patient to rate the pain on a scale with a minimum score of 0 (no pain) and a maximum score of 10 (worst pain).
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of quality of life: The 36-Item Short Form Survey (SF-36)
The quality of life of patients is assessed by the general questionnaire 36-Item Short Form Survey (SF-36) which can be administered by self or hetero-questionnaire. The SF-36 questionnaire was developed from the Medical Outcome Study, a 149-item questionnaire that was developed to assess how the American healthcare system affects the outcome of care. The SF-36 questionnaire is composed of 36 items and makes it possible to assess the physical and mental health of an individual using eleven questions relating to eight aspects of health: Physical activity, limitations due to physical state, physical pain, perceived health, vitality, life and relationship with others, limitations due to the mental state and mental health. Scores between 0 and 100 are determined. Scores tending towards 100 indicate a better quality of life.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of anxiety and depression: The Hospital Anxiety and Depression Scale (HAD)
It is a self-administered questionnaire completed by the patient and based on the Hamilton scale. The HAD scale is a tool for screening for anxiety and depressive disorders. It includes 14 items rated from 0 to 3. Seven questions relate to anxiety (total A) and seven others to the depressive dimension (total D), thus making it possible to obtain two scores (maximum score for each score = 21).
To screen for anxiety and depressive symptomatology, the following interpretation can be proposed for each of the scores (A and D): ≤ 7: normal case; 8 to 10: borderline case; ≥ 11: abnormal case.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of physical activity: International Physical Activity Questionnaire - Short Form
IPAQ assesses physical activity undertaken across a comprehensive set of domains including leisure time, domestic and gardening (yard) activities, work-related and transport-related activity; The IPAQ short form asks about three specific types of activity undertaken in the three domains introduced above and sitting. The specific types of activity that are assessed are walking, moderate-intensity activities and vigorous intensity activities; frequency (measured in days per week) and duration (time per day) are collected separately for each specific type of activity. The items were structured to provide separate scores on walking; moderate-intensity; and vigorous-intensity activity as well as a combined total score to describe overall level of activity. Computation of the total score requires summation of the duration (in minutes) and frequency (days) of walking, moderate-intensity and vigorous-intensity activity.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Sclerostin dosage
The dosage of sclerostin (pg/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Osteocalcin dosage
The dosage of osteocalcin (µg/L) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 6 mL EDTA tube.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Periostin dosage
The dosage of periostin (pg/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Irisin dosage
The dosage of irisin (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken on 4 mL heparin tube for irisin dosage.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
N-terminal propeptide of procollagen type 1 dosage
The dosage of N-terminal propeptide of procollagen type 1 (P1NP) (µg/l) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Dickkopf-related protein 1 dosage
The dosage of Dickkopf-related protein 1 (pg/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 5 mL dry tubes
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
C-terminal telopeptides of collagen type 1 dosage
The dosage of C-terminal telopeptides of collagen type 1 (CTX) (ng/ml) will be performed in order to evaluate bone remodeling. For this purpose, a blood sample will be taken using 6 mL EDTA tube.
Measured: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jun 2025
- Study start3 Sep 2025
- Primary completion1 Dec 2026 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OsteoporosisStudies of the same condition, open and under way.
- More trials run by University Hospital, Clermont-FerrandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Patient will have two visits : Visit 1 - Inclusion visit (informed consent, medical examination, stool sample and test/questionnaires assessing cognition, pain, physical activity, sleep, quality of life, anxiety and depression). -Visit 2 - End of study visit During this visit, a resting-State Functional Magnetic Resonance Imaging will be conducted. Postmenopausal healthy volunteers will have three visits : Visit 1 - Inclusion visit (informed consent, medical examination and bone density test) Visit 2 : stool sample and test/questionnaires assessing cognition, pain, physical activity, sleep, quality of life, anxiety and depression) -Visit 3 - End of study visit During this visit, a resting-State Functional Magnetic Resonance Imaging will be conducted.
- Masking
- None (open label)
- Enrolment
- 66 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Clermont-Ferrand
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Marie-Eva Pickering, Principal investigator, University Hospital, Clermont-Ferrand
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07030205
- Sponsor's protocol ID
- RBHP 2025 PICKERING_ME
- Other IDs
- 2025-A00106-43
- Acronym
- ROSS
- Status last verified
- Jun 2025
- First submitted
- 12 Jun 2025
- Last updated
- 13 May 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Resting-state Imaging and OSteoporosiS
- ClinicalTrials.gov ID
- NCT07030205
- Acronym / sponsor ID
- ROSS / RBHP 2025 PICKERING_ME
- Conditions
- Osteoporosis
- Keywords
- Osteoporosis, Resting state fMRI (rs-fMRI), Cognition
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 66 participants (estimated)
- Lead sponsor
- University Hospital, Clermont-FerrandUniversity, hospital or other
- Study start
- 3 Sep 2025 (actual)
- Primary completion
- 1 Dec 2026 (estimated)
- Study completion
- 1 Dec 2027 (estimated)
- First posted
- 22 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will be conducted in 20 postmenopausal healthy volunteers, 20 postmenopausal osteoporotic patients with fracture and 20 postmenopausal osteoporotic women without fracture, in order to compare functional connectivity between brain areas. Participants will complete different questionnaires and tests assessing cognition, quality of life, sleep, physical activity, pain, anxiety and depression. A biological sample will be performed in order to evaluate different markers of bone remodeling. A Resting-state functional magnetic resonance imaging (rs-fMRI) will be realized in order to establish functional connectivity between brain regions.
Study design
- Primary purpose
- Other
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- Patient will have two visits : Visit 1 - Inclusion visit (informed consent, medical examination, stool sample and test/questionnaires assessing cognition, pain, physical activity, sleep, quality of life, anxiety and depression). -Visit 2 - End of study visit During this visit, a resting-State Functional Magnetic Resonance Imaging will be conducted. Postmenopausal healthy volunteers will have three visits : Visit 1 - Inclusion visit (informed consent, medical examination and bone density test) Visit 2 : stool sample and test/questionnaires assessing cognition, pain, physical activity, sleep, quality of life, anxiety and depression) -Visit 3 - End of study visit During this visit, a resting-State Functional Magnetic Resonance Imaging will be conducted.
| Arm | Type | Receives |
|---|---|---|
| Postmenopausal Healthy volunteers | Experimental | Other: Blood sample, Other: Bone density exam, Other: Tests and questionnaires of study, Other: Functional connectivity value of brain networks at rest22 postmenopausal healthy women, matched by age, menopausal status, socio-educational level and manual laterality, will be included in this study |
| Postmenopausal osteoporotic patients with fracture | Experimental | Other: Blood sample, Other: Tests and questionnaires of study, Other: Functional connectivity value of brain networks at rest22 Postmenopausal osteoporosis patients with fractures will be included in this study |
| Postmenopausal osteoporotic patient without fracture | Experimental | Other: Blood sample, Other: Tests and questionnaires of study, Other: Functional connectivity value of brain networks at rest22 Postmenopausal osteoporosis patients without fractures will be included in this study. |
Who may qualify
- Ages
- 50 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Women aged 50 or over, with postmenopausal osteoporosis, fractured or not, diagnosed by their rheumatologist,
- Able to give informed consent to participate in the research,
- Affiliation with the French Social Security.
- Women aged 50 or over,
- Bone densitometry performed as part of the protocol, not suggestive of osteoporosis and validated by investigators,
Key exclusion criteria (7 listed)
- Presence of pacemaker,
- Presence of medical devices (implants or prostheses),
- Incompatibility of the patient with the safety criteria of the medical imaging center for carrying out magnetic resonance experiments at 3 Tesla,
- Contraindications to the realization of MRI without injection such as claustrophobia proven, hearing aid, pacemaker wearers, wearing a brain clip,
- Refusal to be informed in the event of the accidental discovery of an anomaly during the resting state functional magnetic resonance imaging,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blood sampleA blood sample (fasting), for biobanking purposes to measure certain bone biological markers known to be indicators of bone remodeling (osteocalcin, sclerostin, periostin, irisin, procollagen type 1 N-terminal propeptide (P1NP), Dickkopf-related protein 1 (DKK1), and collagen type 1 C-terminal telopeptides (CTX)). | Other | Postmenopausal Healthy volunteers, Postmenopausal osteoporotic patient without fracture, Postmenopausal osteoporotic patients with fracture |
| Bone density examA bone density exam will be performed in order to verify the non-osteoporotic status of the healthy volunteers group. | Other | Postmenopausal Healthy volunteers |
| Tests and questionnaires of studyAn assessment of cognitive functions will be realized using Montreal Cognitive Assessment (MoCA), Cantab® tests (MOT, MTS, RTI, DGS), the Trail Making Test (TMT), verbal fluency, the Stroop test, the Dubois 5-word test, and the oral picture naming test. Other questionnaires will be used, assessing: sleep quality (Pittsburgh Physical Activity Questionnaire (PSQI)), anxiety and depression (the anxiety/depression scale (HAD)), quality of life (Short Form-36 quality of life questionnaire (SF-36)), physical activity (International Physical Activity Questionnaire (IPAQ)), and pain with the Brief Pain Inventory questionnaire (BPI) and the numerical scale (EN). | Other | Postmenopausal Healthy volunteers, Postmenopausal osteoporotic patient without fracture, Postmenopausal osteoporotic patients with fracture |
| Functional connectivity value of brain networks at restA Resting-State Functional Magnetic Resonance Imaging will be conducted in order to evaluate and compared functional connectivity value of brain networks at rest between three groups. | Other | Postmenopausal Healthy volunteers, Postmenopausal osteoporotic patient without fracture, Postmenopausal osteoporotic patients with fracture |
Primary outcome
Functional connectivity value of brain networks at rest
Time frame: At visit 2 (end of study visit, up to fifteen days after inclusion) for osteoporotic patient group and at visit 3 (end of study visit, up to one month after inclusion) for healthy volunteers group.
The primary outcome is the functional connectivity value of brain networks at rest, calculated from resting-state fMRI data.
23 secondary outcomes
Evaluation of cognitive function (MoCA test)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Cantab test: MOT)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (CANTAB test: Reaction Time (RTI)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (CANTAB test: Digit Span)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (CANTAB test: Match to Sample Visual Search)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Trail Making Test)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Stroop test)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Verbal fluency test)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (5 words test)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of cognitive function (Oral Picture Naming Test)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
The Pittsburgh Sleep Quality Index (PSQI)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of pain: The Brief Pain Inventory Questionnaire (BPI)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of pain: Numerical pain scale
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of quality of life: The 36-Item Short Form Survey (SF-36)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of anxiety and depression: The Hospital Anxiety and Depression Scale (HAD)
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Evaluation of physical activity: International Physical Activity Questionnaire - Short Form
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Sclerostin dosage
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Osteocalcin dosage
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Periostin dosage
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Irisin dosage
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
N-terminal propeptide of procollagen type 1 dosage
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Dickkopf-related protein 1 dosage
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
C-terminal telopeptides of collagen type 1 dosage
Time frame: At inclusion visit (Day 0) for osteoporotic patient group and at visit 2 (up to fifteen days after inclusion) for healthy volunteers group.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 May 2026.
- Individual participant dataSharing planned: No
Related trials for Osteoporosis
Enrolling by invitationObservational study
GRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP)
Osteoporosis
RecruitingObservational study
Glucocorticoid-induced Osteoporosis in Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis
Osteoporosis, Inflammatory Rheumatism
Not yet recruiting
Exercise and Fall Prevention for Fracture Reduction
Osteopenia, Osteoporosis
Active, not recruiting
Impact of Screening and Multicomponent Exercise on Fall Rates, Fractures, and Cardiovascular Health in Diabetes
Type 2 Diabetes, Osteoporosis
Recruiting
Surgeon-Initiated Bone Health Referral Pathway in Patients Undergoing Lower Extremity Arthroplasty
Osteoporosis, Arthroplasty Complications
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Marie-Eva Pickering principal investigator
University Hospital, Clermont-Ferrand
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blood sample, Bone density exam and Tests and questionnaires of study in people with Osteoporosis, run by University Hospital, Clermont-Ferrand at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 13 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lise Laclautre (334.73.754.963, promo_interne_drci@chu-clermontferrand.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Functional connectivity value of brain networks at rest (time frame: At visit 2 (end of study visit, up to fifteen days after inclusion) for osteoporotic patient group and at visit 3 (end of study visit, up to one month after inclusion) for healthy volunteers group.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 May 2026.